Cencora stock forecast

Cencora's weighted forecast puts the share price at $351.97 in October 2027 and $411.05 in October 2029. It hinges on earnings growth, specialty acquisition returns, cash conversion and the valuation multiple.

Where could Cencora's shares be by 2029?

The weighted forecast puts the share price at $351.97 in October 2027, a 4% return including dividends. It reaches $411.05 in October 2029, a 23% return including dividends. Bear probability is 25%. Base probability is 55%. Bull probability is 20%.

What has to go right or wrong for Cencora?

The bear case gives earnings of $2,850 million and $3,000 million in the first two windows, then $3,100 million. Its margins stay near 0.83% to 0.84% because of weaker volumes, customer pressure and financing costs. The bull case reaches $4,100 million and $4,600 million before $5,100 million, requiring specialty growth and better mix to lift margins toward 1.19%. The evidence supports progress: FY2025 revenue grew 9.3%, and the latest quarter showed adjusted operating income growth of 17.0%. But GLP-1 sales have modest profitability, and customer concentration remains high.

The bear case requires slower GLP-1 growth, customer losses or repricing, and acquired businesses that add revenue without covering financing and integration costs. By October 2027 it produces $225.36, falling to $215.97 by October 2029. The 25% probability reflects thin margins, concentrated customers, debt and working-capital demands, although the adjusted earnings record and current operating guidance make sustained downside less likely than base progress.

How much cash does Cencora really make?

Cash from operations is cash produced before capital spending. Free cash flow subtracts spending on warehouses, equipment and technology. “Real” free cash flow goes further by subtracting stock-based compensation, because issuing shares still dilutes owners even when it does not immediately use cash.

What does an investor pay for Cencora today?

The price-to-earnings ratio, or P/E, shows what investors pay for each dollar of annual earnings. Cencora’s trailing P/E is much higher than its next-twelve-month P/E, which means the market expects earnings to rise. But fiscal Q2 2026 GAAP diluted earnings per share were $8.40, compared with $4.75 on an adjusted basis. GAAP includes a $1.1 billion OneOncology remeasurement gain; adjusted earnings remove it. The adjusted figure better shows the operating trend, though acquisition and legal costs still deserve scrutiny.